Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
The EMBO Journal|September 18, 2020
Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesisEric P Kusnadi, Anna S Trigos, Carleen Cullinane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2013
Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancerDariush Etemadmoghadam, George Au-Yeung, Meaghan Wall, et al.
Pigment Cell & Melanoma Research|February 6, 2014
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell linesRichard J Young, Kelly Waldeck, Claire Martin, et al.
Oncotarget|July 9, 2016
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingJaclyn Quin, Keefe T Chan, Jennifer R Devlin, et al.
Cancer Discovery|March 28, 2018
Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant GrowthHelen B Pearson, Jason Li, Valerie S Meniel, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2013
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitorsKaren E Sheppard, Carleen Cullinane, Katherine M Hannan, et al.
Molecular Cancer Therapeutics|October 5, 2013
Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificitiesAndrea Newbold, Geoffrey M Matthews, Michael Bots, et al.
The Journal of Clinical Investigation|January 5, 2012
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in miceKathryn M Kinross, Karen G Montgomery, Margarete Kleinschmidt, et al.
Cancer Cell|July 14, 2012
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53Megan J Bywater, Gretchen Poortinga, Elaine Sanij, et al.
Cancer Discovery|January 29, 2014
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysisTiffany J Parmenter, Margarete Kleinschmidt, Kathryn M Kinross, et al.
Pageof 11